Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PARG | Q86W56 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371238 | 0.90 | JAK2 (0.34) | EEF2KOPRM1OPRK1OPRL1JAK2 | |
| SCHEMBL6371708 | 0.86 | KCNH2 (0.37) | EEF2KOPRM1OPRK1OPRL1JAK2 | |
| SCHEMBL6371072 | 0.81 | EEF2K (0.35) | EEF2KOPRL1JAK2JAK1JAK3 | |
| SCHEMBL6371180 | 0.81 | KCNH2 (0.33) | EEF2KOPRL1JAK2JAK1JAK3 | |
| SCHEMBL6377144 | 0.80 | EEF2K (0.33) | EEF2KJAK2JAK1JAK3LMNA | |
| SCHEMBL6379079 | 0.80 | KCNH2 (0.42) | — | |
| SCHEMBL6378795 | 0.80 | PTPN11 (0.34) | LMNAPTPN11 | |
| SCHEMBL6371429 | 0.79 | TK1 (0.36) | EEF2KOPRK1JAK2JAK1JAK3 | |
| SCHEMBL6370154 | 0.79 | TK1 (0.36) | EEF2KJAK2JAK1JAK3TYK2 | |
| SCHEMBL6372031 | 0.77 | KCNH2 (0.37) | EEF2KOPRM1OPRK1OPRL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | claimed |
| US-20050096278-A1 | Antibacterial agents | ELLSWORTH EDMUND L (US) | 2005-05-05 | — | — | US | claimed |
| WO-2005026145-A2 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050096278-A1 | Antibacterial agents | ELLSWORTH EDMUND L (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005026145-A2 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096278-A1 | Antibacterial agents | MRPL21, FBL, SDHA | EEF2K 715/4885OPRM1 1772/4885OPRK1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.